Analysts Set Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) PT at $58.89

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $58.89.

A number of equities research analysts have recently issued reports on IMCR shares. Oppenheimer boosted their price target on shares of Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. JPMorgan Chase & Co. cut their price target on shares of Immunocore from $54.00 to $50.00 and set an "overweight" rating on the stock in a research note on Monday, April 14th. Morgan Stanley reiterated an "equal weight" rating and set a $35.00 price target on shares of Immunocore in a research note on Friday, March 7th. Deutsche Bank Aktiengesellschaft initiated coverage on Immunocore in a report on Tuesday, May 27th. They issued a "buy" rating and a $65.00 price target on the stock. Finally, Wall Street Zen upgraded Immunocore from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th.

Institutional Investors Weigh In On Immunocore

Several institutional investors and hedge funds have recently added to or reduced their stakes in IMCR. Checkpoint Capital L.P. acquired a new stake in Immunocore in the first quarter valued at approximately $267,000. Banque Transatlantique SA acquired a new position in Immunocore during the 1st quarter valued at about $278,000. Frazier Life Sciences Management L.P. increased its holdings in shares of Immunocore by 176.9% during the first quarter. Frazier Life Sciences Management L.P. now owns 301,170 shares of the company's stock valued at $8,936,000 after purchasing an additional 192,408 shares during the period. Baker BROS. Advisors LP raised its stake in shares of Immunocore by 53.3% in the 1st quarter. Baker BROS. Advisors LP now owns 2,322,656 shares of the company's stock worth $68,913,000 after buying an additional 807,338 shares in the last quarter. Finally, Royal Bank of Canada raised its holdings in shares of Immunocore by 45.1% in the 1st quarter. Royal Bank of Canada now owns 44,011 shares of the company's stock worth $1,306,000 after purchasing an additional 13,689 shares in the last quarter. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore Stock Up 1.1%

NASDAQ:IMCR traded up $0.37 during mid-day trading on Friday, hitting $33.21. 157,264 shares of the company's stock traded hands, compared to its average volume of 347,164. The company has a market capitalization of $1.67 billion, a P/E ratio of -77.18 and a beta of 0.77. The company has a fifty day moving average of $32.17 and a 200 day moving average of $30.32. Immunocore has a twelve month low of $23.15 and a twelve month high of $41.54. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.31 and a current ratio of 6.36.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.45. Immunocore had a negative net margin of 6.48% and a negative return on equity of 5.86%. The firm had revenue of $125.13 million during the quarter, compared to the consensus estimate of $108.82 million. During the same quarter in the prior year, the firm earned ($0.49) EPS. The company's revenue for the quarter was up 33.6% on a year-over-year basis. On average, analysts forecast that Immunocore will post -0.94 EPS for the current year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.